Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Sato, Hiromi ^a   Hunt, Meredith L ^a,b   Weiner, Joshua J ^a   Hansen, Andrew T ^a,c   Frank, Dara W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MONASH UNIVERSITY   (Australia)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; PROTEIN PCRV; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG; ANTIGEN V, PSEUDOMONAS; BACTERIAL ANTIGEN; BACTERIAL TOXIN; EPITOPE; HYBRID PROTEIN; PORE FORMING CYTOTOXIC PROTEIN;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BETA SHEET; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; ENZYME ASSAY; GENE INSERTION; HUMAN; HUMAN CELL; INTOXICATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; TRANSPOSON; TYPE III SECRETION SYSTEM; ANIMAL; CELL DEATH; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN TERTIARY STRUCTURE; PSEUDOMONAS INFECTION; SECRETION; SHEEP; STRUCTURAL HOMOLOGY;

EUKARYOTA; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA; YERSINIA;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELL DEATH; EPITOPES; HELA CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTATION; PHENOTYPE; PORE FORMING CYTOTOXIC PROTEINS; PROTEIN STRUCTURE, TERTIARY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECOMBINANT FUSION PROTEINS; SHEEP; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 79953167847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018356     Document Type: Article

References (76)

1. Giamarellou H, (2000) Therapeutic guidelines for Pseudomonas aeruginosa infections. Int J Antimicrob Agents 16: 103-106.
2. Lyczak JB, Cannon CL, Pier GB, (2000) Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2: 1051-1060.
3. Crouch BS, Wunderink RG, Jones CB, Leeper KV Jr, (1996) Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109: 1019-1029.
4. Vidal F, et al. (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156: 2121-2126.
5. Roy-Burman A, et al. (2001) Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183: 1767-1774.
6. Schulert GS, et al. (2003) Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 188: 1695-1706.
7. Yahr TL, Mende-Mueller LM, Friese MB, Frank DW, (1997) Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 179: 7165-7168.
8. Cornelis GR, (2006) The type III secretion injectisome. Nat Rev Microbiol 4: 811-825.
9. Galan JE, Wolf-Watz H, (2006) Protein delivery into eukaryotic cells by type III secretion machines. Nature 444: 567-573.
10. Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A, (1997) Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol Microbiol 25: 1125-1139.
11. Ganesan AK, Vincent TS, Olson JC, Barbieri JT, (1999) Pseudomonas aeruginosa exoenzyme S disrupts Ras-mediated signal transduction by inhibiting guanine nucleotide exchange factor-catalyzed nucleotide exchange. J Biol Chem 274: 21823-21829.
12. Goehring UM, Schmidt G, Pederson KJ, Aktories K, Barbieri JT, (1999) The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases. J Biol Chem 274: 36369-36372.
13. Sun J, Barbieri JT, (2003) Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem 278: 32794-32800.
14. Sato H, et al. (2003) The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J 22: 2959-2969.
15. Yahr TL, Vallis AJ, Hancock MK, Barbieri JT, Frank DW, (1998) ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci U S A 95: 13899-13904.
16. Frank DW, (1997) The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol 26: 621-629.
17. Fu H, Coburn J, Collier RJ, (1993) The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proc Natl Acad Sci U S A 90: 2320-2324.
18. Sato H, Feix JB, Frank DW, (2006) Identification of superoxide dismutase as a cofactor for the Pseudomonas type III toxin, ExoU. Biochemistry 45: 10368-10375.
19. Burr SE, Stuber K, Frey J, (2003) The ADP-ribosylating toxin, AexT, from Aeromonas salmonicida subsp. salmonicida is translocated via a type III secretion pathway. J Bacteriol 185: 6583-6591.
20. Pallen MJ, Beatson SA, Bailey CM, (2005) Bioinformatics, genomics and evolution of non-flagellar type-III secretion systems: a Darwinian perspective. FEMS Microbiol Rev 29: 201-229.
21. Troisfontaines P, Cornelis GR, (2005) Type III secretion: more systems than you think. Physiology 20: 326-339.
22. Frithz-Lindsten E, et al. (1998) Functional conservation of the effector protein translocators PopB/YopB and PopD/YopD of Pseudomonas aeruginosa and Yersinia pseudotuberculosis. Mol Microbiol 29: 1155-1165.
23. Caroline G, Eric F, Bohn YS, Sylvie E, Attree I, (2008) Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis. J Biol Chem 283: 23940-23949.
24. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I, (2004) The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 72: 4741-4750.
25. Lee VT, Tam C, Schneewind O, (2000) LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells. J Biol Chem 275: 36869-36875.
26. Schoehn G, Di Guilmi AM, Lemaire D, Attree I, Weissenhorn W, Dessen A, (2003) Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas. EMBO J 22: 4957-4967.
27. Goure J, Broz P, Attree O, Cornelis GR, Attree I, (2005) Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J Infect Dis 192: 218-225.
28. Blocker AJ, et al. (2008) What's the point of the type III secretion system needle? Proc Natl Acad Sci U S A 105: 6507-6513.
29. Sawa T, et al. (1999) Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 5: 392-398.
30. Frank DW, et al. (2002) Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186: 64-73.
31. Holder IA, Neely AN, Frank DW, (2001) PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 69: 5908-5910.
32. Moriyama K, Wiener-Kronish JP, Sawa T, (2009) Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Microbiol Immunol 53: 587-594.
33. Baer M, et al. (2009) An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 77: 1083-1090.
34. Broz P, et al. (2007) Function and molecular architecture of the Yersinia injectisome tip complex. Mol Microbiol 65: 1311-1320.
35. Derewenda U, et al. (2004) The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague. Structure 12: 301-306.
36. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
37. Frank DW, Nair G, Schweizer HP, (1994) Construction and characterization of chromosomal insertional mutations of the Pseudomonas aeruginosa exoenzyme S trans-regulatory locus. Infect Immun 62: 554-563.
38. McCaw ML, Lykken GL, Singh PK, Yahr TL, (2002) ExsD is a negative regulator of the Pseudomonas aeruginosa type III secretion regulon. Mol Microbiol 46: 1123-1133.
39. Quenee LE, et al. (2010) Amino acid residues 196-225 of LcrV represent a plague protective epitope. Vaccine 28: 1870-1876.
40. Vernazza C, Lingard B, Flick-Smith HC, Baillie LW, Hill J, Atkins HS, (2009) Small protective fragments of the Yersinia pestis V antigen. Vaccine 27: 2775-2780.
41. Faure K, et al. (2003) Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines 1: 2.
42. Deane JE, et al. (2006) Molecular model of a type III secretion system needle: Implications for host-cell sensing. Proc Natl Acad Sci U S A 103: 12529-12533.
43. Mueller CA, et al. (2005) The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310: 674-676.
44. Mueller CA, Broz P, Cornelis GR, (2008) The type III secretion system tip complex and translocon. Mol Microbiol 68: 1085-1095.
45. Marenne MN, Journet L, Mota LJ, Cornelis GR, (2003) Genetic analysis of the formation of the Ysc-Yop translocation pore in macrophages by Yersinia enterocolitica: role of LcrV, YscF and YopN. Microb Pathog 35: 243-258.
46. Blocker A, et al. (1999) The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 147: 683-693.
47. Viboud GI, Bliska JB, (2001) A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes. EMBO J 20: 5373-5382.
48. Dacheux D, Attree I, Toussaint B, (2001) Expression of ExsA in trans confers type III secretion system-dependent cytotoxicity on noncytotoxic Pseudomonas aeruginosa cystic fibrosis isolates. Infect Immun 69: 538-542.
49. Cisz M, Lee PC, Rietsch A, (2008) ExoS controls the cell contact-mediated switch to effector secretion in Pseudomonas aeruginosa. J Bacteriol 190: 2726-2738.
50. Sory MP, Cornelis GR, (1994) Translocation of a hybrid YopE-adenylate cyclase from Yersinia enterocolitica into HeLa cells. Mol Microbiol 14: 583-594.
51. Bridge DR, Novotny MJ, Moore ER, Olson JC, (2010) Role of host cell polarity and leading edge properties in Pseudomonas type III secretion. Microbiology 156: 356-373.
52. La Ragione RM, et al. (2006) Recombinant anti-EspA antibodies block Escherichia coli O157:H7-induced attaching and effacing lesions in vitro. Microbes Infect 8: 426-433.
53. Quinaud M, et al. (2007) Structure of the heterotrimeric complex that regulates type III secretion needle formation. Proc Natl Acad Sci U S A 104: 7803-7808.
54. Veenendaal AK, Sundin C, Blocker AJ, (2009) Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191: 563-570.
55. Brubaker RR, (2003) Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 71: 3673-3681.
56. Hill J, Leary SE, Griffin KF, Williamson ED, Titball RW, (1997) Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 65: 4476-4482.
57. Motin VL, Nakajima R, Smirnov GB, Brubaker RR, (1994) Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 62: 4192-4201.
58. Yahr TL, Hovey AK, Kulich SM, Frank DW, (1995) Transcriptional analysis of the Pseudomonas aeruginosa exoenzyme S structural gene. J Bacteriol 177: 1169-1178.
59. Hamad MA, Nilles ML, (2007) Roles of YopN, LcrG and LcrV in controlling Yops secretion by Yersinia pestis. Adv Exp Med Biol 603: 225-234.
60. Lee PC, Stopford CM, Svenson AG, Rietsch A, (2010) Control of effector export by the P. aeruginosa type III secretion proteins PcrG and PcrV. Mol Microbiol 75: 924-941.
61. Martinez-Argudo I, Blocker AJ, (2010) The Shigella T3SS needle transmits a signal for MxiC release, which controls secretion of effectors. Mol Microbiol published online, DOI: 10.1111/j.1365-2958.2010.07413.x.
62. Menard R, Sansonetti PJ, Parsot C, (1993) Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells. J Bacteriol 175: 5899-5906.
63. Menard R, Sansonetti P, Parsot C, (1994) The secretion of the Shigella flexneri Ipa invasins is activated by epithelial cells and controlled by IpaB and IpaD. EMBO J 13: 5293-5302.
64. DeBord KL, Lee VT, Schneewind O, (2001) Roles of LcrG and LcrV during type III targeting of effector Yops by Yersinia enterocolitica. J Bacteriol 183: 4588-4598.
65. Skrzypek E, Straley SC, (1995) Differential effects of deletions in lcrV on secretion of V antigen, regulation of the low-Ca2+ response, and virulence of Yersinia pestis. J Bacteriol 177: 2530-2542.
66. Sundin C, Wolfgang MC, Lory S, Forsberg A, Frithz-Lindsten E, (2002) Type IV pili are not specifically required for contact dependent translocation of exoenzymes by Pseudomonas aeruginosa. Microb Pathog 33: 265-277.
67. Davis AJ, Mecsas J, (2007) Mutations in the Yersinia pseudotuberculosis type III secretion system needle protein, YscF, that specifically abrogate effector translocation into host cells. J Bacteriol 189: 83-97.
68. Espina M, et al. (2006) IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect Immun 74: 4391-4400.
69. Torruellas J, Jackson MW, Pennock JW, Plano GV, (2005) The Yersinia pestis type III secretion needle plays a role in the regulation of Yop secretion. Mol Microbiol 57: 1719-1733.
70. Epler CR, Dickenson NE, Olive AJ, Picking WL, Picking WD, (2009) Liposomes recruit IpaC to the Shigella type III secretion apparatus needle as a final step in secretion induction. Infect Immun 77: 2754-2761.
71. Stensrud KF, et al. (2008) Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip. J Biol Chem 283: 18646-18654.
72. Johnson S, et al. (2007) Self-chaperoning of the type III secretion system needle tip proteins IpaD and BipD. J Biol Chem 282: 4035-4044.
73. Lupas A, (1996) Coiled coils: new structures and new functions. Trends Biochem Sci 21: 375-382.
74. Botteaux A, Sory MP, Biskri L, Parsot C, Allaoui A, (2009) MxiC is secreted by and controls the substrate specificity of the Shigella flexneri type III secretion apparatus. Mol Microbiol 71: 449-460.
75. Overheim KA, et al. (2005) LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73: 5152-5159.
76. Vogel HJ, Bonner DM, (1956) Acetylornithinase of Escherichia coli: partial purification and some properties. J Biol Chem 218: 97-106.